Reviewer's report

Title: Methotrexate myelopathy after intrathecal chemotherapy: a case report

Version: 2 Date: 8 January 2015

Reviewer: Akio Suzumura

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

In this case report, Murata et al presented acute myelopathy after intrathecal methotrexate administration.
This is a rare and interesting case.
There are several minor issues to be addressed as follows,

1. The reason why MTX was administrated intrathecally is unclear. Since the patient had mass in vertebral bones, they did not need to administrate intrathecally.

2. The serum Vit B12 level was rather high. Although the authors mentioned the patient was treated with B12, but it was 1 month before. The authors need the explanation.
3. Because clinical and MRI finding are similar to subacute combined degeneration (SCD), the author should discuss more to deny the patient having SCD.

4. Cranial nervous system should be cranial nerves.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Declaration of competing interests:**

I have no conflict of interests